Board of directors

Sol-Gel directors includes industry veterans as well as world-leading scientists in the fields of dermatology, pharmaceuticals and microencapsulation. Years of applied experience, and deep cross-functional expertise equips Sol-Gel with unique qualities and capabilities.

doctor-2
Dr. Ofra Levy-Hacham
VP Quality Assurance and Regulatory Affairs

Dr. Ofra Levy-Hacham has served as our vice president of quality and regulatory affairs since 2011. Prior to joining Sol-Gel, Dr. Levy-Hacham served as a scientific specialist and project manager at Biotechnology General Ltd., a fully integrated biopharmaceutical services private company from 2010 until 2011. From 2008 until 2010, Dr. Levy-Hacham served as vice president chemistry, manufacturing and controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of various skin lesions and conditions. Dr. Levy-Hacham holds a Ph.D. in chemistry from The Technion - Israel Institute of Technology, Israel.
 

doctor-2
Dr. Ofer Toledano
VP Research and Development

Dr. Ofer Toledano has served as our vice president of research and development since 2004. Prior to joining Sol-Gel, Dr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. (formerly known as Makhteshim Agan Industries Ltd.), an Israeli manufacturer and distributor of crop protection products from 1998 until 2004. Dr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.
 

doctor-2
Dr. Alon Seri-Levy
Co-Founder and Chief Executive Officer

Dr. Alon Seri-Levy co-founded Sol-Gel and has served as our chief executive officer since our
inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-
Gel, Dr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an
Israeli research and development company that specialized in the development of peptide-based
drug products. Dr. Seri-Levy holds a Ph.D. in Chemistry (summa cum laude) from The Hebrew
University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford University,
United Kingdom. Dr. Seri-Levy was appointed to our board of directors immediately following
the pricing of the company’s initial public offering.

doctor-2
בדיקה
CEO

microencapsulation delivery system, consisting of microcapsules made of precipitated silica. Based on our pre-clinical and clinical data, we expect this delivery system will enable us to develop and commercialize dermatological drug products that are more effective or have fewer side effects than currently marketed drugs.

doctor-2
Media Confidence Index

Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing and coializing topical dermatological drug products.
Sol-Gel is a clinical-stage specialty pharmaceutical company focused  commercializing dermatolol drug products.eveloping and commercializing topical dermatological dru
ing topiatological dru

doctor-2
Dr.Addison_Alexander
VP Quality Assurance and Regulatory Affair

Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing and coializing topical dermatological drug products.
Sol-Gel is a clinical-stage specialty pharmaceutical company focused  commercializing dermatolol drug products.eveloping and commercializing topical dermatological dru
ing topiatological dru
 

doctor-2
Media Derived Indicators
fgas

הלחעדלחכי דגשלחילח ידשלךיכע חלשדי חלשדי ךלשילךהילךסבה לךש ןעטשולהילך ןשדי ןשגיעןשילך שידגליה לשדגח גךלכע שגכעשדגכעש גכע שגכ ע

doctor-2
Earnings Prediction Technology

Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing and coializing topical dermatological drug products.
Sol-Gel is a clinical-stage specialty pharmaceutical company focused  commercializing dermatolol drug products.eveloping and commercializing topical dermatological druing topiatological dru